| المؤلفون: |
Yamanaka-Takaichi M; Department of Dermatology, Mayo Clinic, Rochester, Minnesota., Watanabe M; Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Comfere NI; Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory & Pathology, Mayo Clinic, Rochester, Minnesota., Sokumbi O; Department of Dermatology, Mayo Clinic, Jacksonville, Florida; Department of Laboratory & Pathology, Mayo Clinic, Jacksonville, Florida., Akpala CO; Mayo Clinic Alix School of Medicine - Minnesota Campus, Mayo Clinic College of Medicine and Science, Rochester, Minnesota., Todd A; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota., Branch EL; Division of Research Administrative Services, Mayo Clinic, Scottsdale, Arizona., Mangold AR; Department of Dermatology, Mayo Clinic, Scottsdale, Arizona., Hiroyasu S; Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Tsuruta D; Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan., Alavi A; Department of Dermatology, Mayo Clinic, Rochester, Minnesota. Electronic address: alavi.afsaneh@mayo.edu. |
| مستخلص: |
Competing Interests: Conflicts of interest Dr Alavi is on the Board of Directors for the Hidradenitis Suppurativa Foundation and served as a consultant for AbbVie Inc, Boehringer Ingelheim International, InflaRx NV, Novartis Pharmaceuticals Corp, and UCB Inc; and as an investigator for Boehringer Ingelheim International and Processa Pharmaceutical Inc. Dr Yamanaka-Takaichi, Dr Watanabe, Dr Comfere, Dr Sokumbi, Author Akpala, Author Todd, Author Branch, Dr Mangold, Dr Hiroyasu, and Dr Tsuruta have no conflicts of interest to declare. |
Full Text via ClinicalKey 
Full Text Finder